Recent Advances in Multiple Myeloma: Highlights from the IMS 2022 Meeting and Beyond

Surbhi Sidana, MD, and Caitlin Costello, MD, introduce the updated evidence regarding induction regimens for patients with transplant-eligible NDMM and how to select the appropriate induction regimen in this population.

Dr Rebecca Silbermann discusses the results of studies evaluating MRD-response adapted therapy in patients with transplant-eligible NDMM.

Larry Anderson, MD, explains the study design and outcomes of the DETERMINATION study, and sparks a discussion on which patients with NDMM should receive stem cell transplants.

Dr Andrew Cowan describes how the appropriate duration of therapy for patients with transplant-eligible multiple myeloma, and Dr Caitlin Costello discusses her approach to maintenance therapy.

The panel explains their opinions on induction therapy approaches for high-risk and standard-risk patients with NDMM.

Caitlin Costello, MD, describes how to determine if a patient with MM is transplant-ineligible, and some factors to take into consideration when choosing a treatment regimen.

Dr Larry Anderson summarizes the study design and updated data of the MAIA trial, and Dr Rebecca Silbermann compares it against the SWOG 0777 trial.

Andrew Cowan, MD, presents the results of the ENDURANCE study comparing two triplet regimens in transplant-ineligible MM.

Dr Caitlin Costello discusses how she adapts treatment to patients with transplant-ineligible NDMM based on fitness level, and why some patients receive doublet therapy.

Experts explain their approaches to maintenance therapy for patients with transplant-ineligible NDMM and when therapy should be reduced.

Drs Sidana and Silbermann describe the currently available treatment options for early- and late-relapse MM, and how to select an appropriate regimen.

An explanation of the mechanism of action of bispecific antibodies and their use in relapsed/refractory multiple myeloma treatment.

Key opinion leaders compare the overall benefits of CAR-T therapy and share some advice for managing the toxicities of CAR-T therapy as a patient transitions back to their local doctor.

Dr Silbermann continues her discussion of BCMA-targeting agents with a look at data on the use of bispecific agents for R/R MM treatment after a patient has already received a BCMA therapy.

Drs Cowan and Anderson review whether older agents such as isa-based regimens still have a place in R/R MM treatment after the introduction of bispecific agents and CAR-T therapy.

Closing out their discussion, the panel highlights unmet needs in multiple myeloma that clinicians and patients still face.

A panel of experts in multiple myeloma discusses recent data updates from 2022 International Myeloma Society Annual Meeting and how it influences treatment strategies in clinical practice.